Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.
RBC Capital Maintains Outperform on Mercury Systems, Lowers Price Target to $66
RBC Capital analyst Ken Herbert maintains Mercury Systems (NASDAQ:MRCY) with a Outperform and lowers the price target from $72 to $66.